These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 34218776

  • 21. Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib.
    De Bondt M, Renders J, de Prado PP, Berghmans N, Pörtner N, Vanbrabant L, de Oliveira VLS, Duran G, Baeten P, Broux B, Gouwy M, Matthys P, Hellings N, Struyf S.
    J Leukoc Biol; 2024 Jul 08. PubMed ID: 38976501
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M, Renders J, Struyf S, Hellings N.
    Autoimmun Rev; 2024 May 08; 23(5):103532. PubMed ID: 38521213
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S, Dammeijer F, Hendriks RW.
    Mol Cancer; 2018 Feb 19; 17(1):57. PubMed ID: 29455639
    [Abstract] [Full Text] [Related]

  • 27. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
    Himmelbauer MK, Bajrami B, Basile R, Capacci A, Chen T, Choi CK, Gilfillan R, Gonzalez-Lopez de Turiso F, Gu C, Hoemberger M, Johnson DS, Jones JH, Kadakia E, Kirkland M, Lin EY, Liu Y, Ma B, Magee T, Mantena S, Marx IE, Metrick CM, Mingueneau M, Murugan P, Muste CA, Nadella P, Nevalainen M, Parker Harp CR, Pattaropong V, Pietrasiewicz A, Prince RJ, Purgett TJ, Santoro JC, Schulz J, Sciabola S, Tang H, Vandeveer HG, Wang T, Yousaf Z, Helal CJ, Hopkins BT.
    J Med Chem; 2024 May 23; 67(10):8122-8140. PubMed ID: 38712838
    [Abstract] [Full Text] [Related]

  • 28. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L.
    J Med Chem; 2019 Sep 12; 62(17):7643-7655. PubMed ID: 31368705
    [Abstract] [Full Text] [Related]

  • 29. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
    Geladaris A, Torke S, Saberi D, Alankus YB, Streit F, Zechel S, Stadelmann-Nessler C, Fischer A, Boschert U, Häusler D, Weber MS.
    Acta Neuropathol; 2024 Apr 24; 147(1):75. PubMed ID: 38656399
    [Abstract] [Full Text] [Related]

  • 30. Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination.
    Elkjaer ML, Waede MR, Kingo C, Damsbo K, Illes Z.
    Front Immunol; 2023 Apr 24; 14():1264128. PubMed ID: 38022591
    [Abstract] [Full Text] [Related]

  • 31. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
    Nadeem A, Ahmad SF, Al-Harbi NO, El-Sherbeeny AM, Alasmari AF, Alanazi WA, Alasmari F, Ibrahim KE, Al-Harbi MM, Bakheet SA, Attia SM.
    Int Immunopharmacol; 2020 Mar 24; 80():106215. PubMed ID: 31982823
    [Abstract] [Full Text] [Related]

  • 32. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE, Wampole M, Oberoi K.
    Front Immunol; 2021 Mar 24; 12():662223. PubMed ID: 34803999
    [Abstract] [Full Text] [Related]

  • 33. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, Krupa A, Pawlak D.
    Molecules; 2023 Mar 06; 28(5):. PubMed ID: 36903645
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS.
    Mult Scler; 2024 Apr 06; 30(4-5):558-570. PubMed ID: 38436271
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.
    Li R, Tang H, Burns JC, Hopkins BT, Le Coz C, Zhang B, de Barcelos IP, Romberg N, Goldstein AC, Banwell BL, Luning Prak ET, Mingueneau M, Bar-Or A.
    Acta Neuropathol; 2022 Apr 06; 143(4):505-521. PubMed ID: 35303161
    [Abstract] [Full Text] [Related]

  • 38. Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.
    Shulga O, Chabanova A, Kotsiuba O.
    Postep Psychiatr Neurol; 2023 Mar 06; 32(1):23-30. PubMed ID: 37287740
    [Abstract] [Full Text] [Related]

  • 39. Therapies for multiple sclerosis targeting B cells.
    Milo R.
    Croat Med J; 2019 Apr 30; 60(2):87-98. PubMed ID: 31044580
    [Abstract] [Full Text] [Related]

  • 40. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
    Mendes-Bastos P, Brasileiro A, Kolkhir P, Frischbutter S, Scheffel J, Moñino-Romero S, Maurer M.
    Allergy; 2022 Aug 30; 77(8):2355-2366. PubMed ID: 35175630
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.